News | April 28, 2010

Experts Compare Notes on SBRT, SRS Techniques

April 28, 2010 - New approaches to image-guidance and motion management are making it possible to successfully target lung, liver and spinal tumors, which are hard to reach even with instruments like stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS).

In a symposium in New York earlier this month, leading clinical experts who have treated more than 3,800 patients with SBRT or SRS, spoke about their own experiences with the technology.

Robert Timmerman, M.D., of the University of Texas Southwestern Medical Center, presented findings from RTOG 0236, a recent multicenter study of SBRT in the treatment of medically inoperable lung cancer patients. At three years post-treatment, the rate of overall survival for these study patients was 56 percent, as compared with historical survival rates of 30 to 50 percent for similar patients treated with conventional radiation. The primary tumor control rate was extremely high at 97.6 percent. Dr. Timmerman noted, "That is more than double the rate of primary tumor control achieved in earlier studies where conventional radiotherapy was used."

Yoshiya Yamada, M.D., Memorial Sloan-Kettering Cancer Center of New York, talked about the role of radiosurgery in managing spine metastases. He said spine radiosurgery is effective for patients who do not have any spinal compression, and he noted the literature consistently shows local control rates of up to 85 percent for these patients. "They often experience near complete pain relief," he said.

By injecting and staining tumors with an iodine-rich oil, Martin Fuss, M.D., professor of radiation medicine at the Oregon Health and Science University in Portland, can more clearly see the image-guidance tools. Dr. Fuss uses intensity-modulated radiation therapy (IMRT) and the RapidArc delivery technique on the Novalis Tx system from Varian and BrainLAB to deliver SBRT treatments for liver tumors. With the enhanced visualization technique, he can concentrate high doses on tumors, while achieving a sharper reduction in dose to tissue around the tumor.

For more information:

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Overlay Init